THE SHADOW OF DIABETES CARE IN OLDER ADULTS FRANCISCO DIAZ GNP-BC, CDE
|
|
- Catherine Hillary Gibbs
- 5 years ago
- Views:
Transcription
1 THE SHADOW OF DIABETES CARE IN OLDER ADULTS FRANCISCO DIAZ GNP-BC, CDE
2 OBJECTIVES 1- Name 3 geriatric syndromes that impact DM care 2- Name the targets glycemic goals of care for older adults as recommended by American Diabetes Association 3- Name 3 anti-diabetes medications with high risk for hypoglycemia 4- Able to assess and to manage a hypoglycemic episode
3 INTRODUCTION million adult New Yorkers diagnosed with diabetes and 760,000 may not know that they have it 5 million have prediabetes diabetes related costs In NY $1.2 billion 2013 death attributed to DM; likely under counted because the identified cause would be cardiovascular disease but diabetes contributes to it Between death per 100,000 5 th cause of death in NY. (DiNapoli, T, 2015; CDC, 2015)
4 STANDARDS OF CARE FOR OLDER ADULTS American Diabetes Association Clin Diabetes 2018;36:14-37
5 GOALS & SETTING CRITERIA FOR OLDER ADULTS Adapted from: American Diabetes Association Clin Diabetes 2018;36: s119-s125 Patient Characteristics / Health Status Rationale A1c goal Healthy: Few coexisting chronic illnesses intact cognitive and functional status Complex / Intermediate: Multiple co-existing chronic illnesses or 2+ instrumental ADL impairments or mild- to moderate cognitive impairment Very complex/ poor health : LTC or end-stage chronic illnesses or moderate to- severe cognitive impairment or 2+ ADS dependencies Longer remaining life expectancy < 7.5% Fingerstick: mgdl Intermediate remaining life expectancy high treatment burden hypoglycemia vulnerability fall risk Limited remaining life expectancy Makes benefit uncertain <8.0% Finger stick: mgdl <8.5% Finger stick: mgdl
6 HYPOGLYCEMIA
7 IDENTIFICATION OF HYPOGLYCEMIA IN OLDER ADULTS Difficulties recognizing hypoglycemia in older adults Symptoms are not specific Easily misdiagnosed : stroke, vertigo, visual disturbance Atypical presentation e.g confusion or hypoactive delirium Unawareness of symptoms Patient who have impaired cognition are unable to communicate their feelings or symptoms
8 CONSEQUENCES OF HYPOGLYCEMIA Consequences of hypoglycemia Physical cognitive and functional dependence Recurrent falls Increased risks for fractures, frailty, mortality Behavioral changes : anxiety, fears, social Isolation Recurrent hospitalizations Increased risks for institutionalization
9 WHY SHOULD WE CARE?
10 HOW TO MANAGE HYPOGLYCEMIA 4 OUNCES X3 The National Diabetes Education Initiative
11 MEDICAL MANAGEMENT OF DIABETES CONSIDERING HYPOGLYCEMIA : PATOPHYSIOLOGY GLP1 SU TZD DDP4 INS GLP1 TZD SGLT2 GLP1 MET TZD GLP1 MET INS
12 Medical Management of diabetes : New Paradigm Abdul-Ghani,M and DeFronzo, R Diabetes Care 2017 Aug; 40(8):
13 ANTI DIABETES MEDICATIONS PER HYPOGLYCEMIA RISK
14 INSULINS
15 MONITORING
16 INSULIN PUMPS
17 APPS. DMES
18 CONSIDERATIONS: Type of Diabetes, Presence of complications, years with diabetes, past treatments Medications: how glucose levels will be affected AFTER taking the medications, inconsistent eating Episodes of hypoglycemia: provide events medication use, changes in eating pattern or type, increased activities, constitutional symptoms, was it asymptomatic. Measuring, keeping track of : foods, medications, exercise Before an appointment to a professional that will assess diabetes: check fasting, pre- meal and/ or 2 hours post meal for 2 days Emergency: glucagon pen, Personal Emergency Response system and Medic Alert Bracelet Possibility of driving, operating machinery, living alone, support system
19 CONCLUSION For older adults the benefits vs risks ratio of diabetes care is rather narrow; but now a days there are less riskier alternatives and possibilities to tailor it to those who would stand to benefit the least. Presence of hypoglycemia should be consider seriously, treated, prevented and, eventually, it should lead to reconsideration of the diabetes care to older adults.
20 RESOURCES General information: Diabetes Care Supplies, Medication Coverage : MLN/MLNMattersArticles/downloads/SE1008.pdf Sick Days & Emergency Preparedness:
21 SUPREME VIGILANCE
22 REFERENCES Abdelhafiz, A., Rodríguez-Mañas, L., Morley, J., & Sinclair, A. (2015). Hypoglycemia in Older People - A Less Well Recognized Risk Factor for Frailty. Aging And Disease, 6(2), Abdul-Ghani, M., & DeFronzo, R. (2017). Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. Diabetes Care, 40(8), American Diabetes Association. (2017). 11. Older Adults: Standards of Medical Care in Diabetes Diabetes Care, 41(Supplement 1), S119-S Holst, J., & Orskov, C. (2004). The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism. Diabetes, 53(Supplement 3), S197-S Kirsh, S., & Aron, D. (2011). Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus. Drugs & Aging, 28(12), Lipska, K., Krumholz, H., Soones, T., & Lee, S. (2016). Polypharmacy in the Aging Patient. JAMA, 315(10), Rawlings, K. (2013). Sonia Sotomayor: Her Life With Diabetes. Diabetes Forecast. Retrieved 11 February 2018, from Stats of the State of New York. (2018). Cdc.gov. Retrieved 25 February 2018, from
7/28/17. Objectives: Hypoglycemia Unawareness in the Geriatric Patient: A Safety Concern. Disclaimer:
Hypoglycemia Unawareness in the Geriatric Patient: A Safety Concern 29TH ANNUAL TNP CONFERENCE TRANSFORMING HEALTHCARE IN TEXAS SEPTEMBER 8, 2017 AUSTIN, TEXAS Kenneth Lowrance, DNP, APRN, CNS, FNP-BC,
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population
More informationLOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA
LOW SUGAR: CAUSES, COMPLICATIONS AND MANAGEMENT OF HYPOGLYCEMIA Anne Leake, PhD, APRN-Rx, BC-ADM ECHO Diabetes Learning Group 3/28/2018 Objectives 1. Identify common preventable causes of hypoglycemia
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationIt Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia
It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia Jacqueline LaManna, PhD, ANP BC, BC ADM, CDE Holly Divine, PharmD, BCACP, CGP, CDE, FAPhA Disclosures Dr. Jacqueline LaManna
More informationSpecial thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic
Special thanks to the EJC Foundation for their support of Sanford Center Geriatric Specialty Clinic Sanford Center for Aging 775-784-4744 med.unr.edu/aging Diabetes Management Series: From Selfmanagement
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationCASE A2 Managing Between-meal Hypoglycemia
Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationDiabetes Management. Honoring Choice and Positive Outcomes for. in Older Adults. Nutrition Connection. by Brenda Richardson, MA, RDN, LD, CD, FAND
Nutrition Connection by Brenda Richardson, MA, RDN, LD, CD, FAND Honoring Choice and Positive Outcomes for Diabetes Management in Older Adults 16 As healthcare providers, we focus on offering support in
More informationCorporate Medical Policy
Corporate Medical Policy Continuous Monitoring of Glucose in the Interstitial Fluid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: continuous_monitoring_of_glucose_in_the_interstitial_fluid
More informationCommon Diabetes-related Terms
Common Diabetes-related Terms A1C An A1C test measures a person's average blood glucose level over two to three months. Hemoglobin is the part of a red blood cell that carries oxygen to the cells and sometimes
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationOlder Adults & Optimal Outcome. Individualizing Diabetes Management. Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC
Older Adults & Optimal Outcome Individualizing Diabetes Management Mary Moyer Janci BC-FNP BC-ADM CDE Teaching Associate Diabetes Care Center UWMC What is Diabetes? METABOLIC DISEASE Food breakdown (carbohydrates,
More informationObjectives. The Problem. We ve come a LONG way, Innovations in Diabetes Care and Management. Barbara Walz, RN, BSN, CDE April 26, 2018
Objectives Innovations in Diabetes Care and Management Barbara Walz, RN, BSN, CDE April 26, 2018 1. Briefly discuss the history of diabetes management over the past 100 years 2. Describe the impact of
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationIncorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA
Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationRationalizing Medications. Tan Jianming Senior Pharmacist KTPH
Rationalizing Medications Tan Jianming Senior Pharmacist KTPH + Older patients are more likely to: 2 Have multiple co-morbid diseases Have age-related physiological changes that result in a reduced tolerance
More informationNORTHEAST OHIO VA HEALTHCARE SYSTEM BEST PRACTICE RECOGNITION/MANAGEMENT OF HYPOGLYCEMIA
NORTHEAST OHIO VA HEALTHCARE SYSTEM BEST PRACTICE RECOGNITION/MANAGEMENT OF HYPOGLYCEMIA Joint Commission Inpatient Diabetes Team Sharon A. Watts DNP, FNP-BC, CDE Drina Nemes MSN, CNS, CRRN Amanda Pensiero
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationDiabetes treatment by the algorithm
Diabetes treatment by the algorithm Joseph Dawley, M.D. Southwest Oklahoma Family Medicine Residency Oklahoma University Health Sciences Center Clinical Assistant Professor Objectives By the end of this
More informationDIABETES EDUCATION FOR HEALTH CARE SERIES
American Association of Diabetes Educators Provider is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. DIABETES EDUCATION
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationObjectives 10/11/2013. Diabetes- The Real Cost of Sugar. Diabetes 101: What is Diabetes. By Ruth Nekonchuk RD CDE LMNT
Diabetes- The Real Cost of Sugar By Ruth Nekonchuk RD CDE LMNT Objectives To explain diabetes To explain the risks of diabetes To enumerate the cost of diabetes to our country To enumerate the cost of
More informationA Call to Action: Addressing Diabetes Medication Safety
A Call to Action: Addressing Diabetes Medication Safety Evan M. Klass, M.D., F.A.C.P. Senior Associate Dean, Statewide Initiatives Reducing ED visits for insulin induced hypoglycemia is a Healthy People
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationCommon Drug Review Patient Group Input Submissions
Common Drug Review Patient Group Input Submissions empagliflozin and metformin (Synjardy) for Diabetes mellitus (Type 2) Patient group input submissions were received from the following patient groups.
More informationContinuous Glucose Monitoring Devices Pharmacy Policy
Line of Business: All Line of Business Effective date: August 16, 2017 Revision date: August 16, 2017 Continuous Glucose Monitoring Devices Pharmacy Policy This policy has been developed through review
More informationMetabolic Syndrome: What s so big about BIG?
Tuesday, 10:00 11:30, A2 Objectives: Notes: Metabolic Syndrome: What s so big about BIG? Patrice Conrad pbconrad1@att.net 1. Identify advances in clinical assessment and management of selected healthcare
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationDiabetes Complications Recognition and Treatment
Diabetes Complications Recognition and Treatment Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Diabetes is the most difficult of all
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationPhysical Activity/Exercise Prescription with Diabetes
Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity
More informationWelcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.
Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This questionnaire is for Jardiance (empagliflozin). Patient Groups have to register before
More informationLong-Term Care Updates
Long-Term Care Updates January 2019 By Kristina Nikl, PharmD Several recent studies evaluating the management of diabetes in older adults have concluded that 25-52% of elderly patients are currently being
More informationFrailty and Type 2 Diabetes Guidelines for clinicians
H.G. WELLS PROJECT Frailty and Type 2 Diabetes Guidelines for clinicians Victoria Ruszala victoria.ruszala@nhs.net H.G. Wells Project team Dugal T, Partington E. Kernow CCG Diabetes and Frailty Guideline
More informationDiabetes Prevention (Managing Prediabetes)
IMPORTANCE OF FOCUS Although Prediabetes is not viewed as a clinical entity in its own right, it is a risk factor for diabetes and cardiovascular disease. It is estimated that approximately 1 in 3 U.S.
More informationWelcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process.
Welcome to BC PharmaCare's Public Input Questionnaire for drugs being reviewed under the B.C. Drug Review Process. This questionnaire is for Forxiga (dapagliflozin). Patient Groups have to register before
More informationDIABETES UPDATE 2018
DIABETES UPDATE 2018 Jerome V. Tolbert, M.D., Ph.D. Assistant Professor of Medicine Icahn School of Medicine at Mt. Sinai Division of Endocrinology and Bone Diseases 317 East 17 th Street New York, New
More informationGeriatrics and Cancer Care
Geriatrics and Cancer Care Roger Wong, BMSc, MD, FRCPC, FACP Postgraduate Dean of Medical Education Clinical Professor, Division of Geriatric Medicine UBC Faculty of Medicine Disclosure No competing interests
More informationWhy do we care? 20.8 million people. 70% of people with diabetes will die of cardiovascular disease. What is Diabetes?
What is Diabetes? Diabetes 101 Ginny Burns RN MEd CDE Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action
More informationMeeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting
Meeting the Challenge of Inpatient Glycemic Management in the Non-Critical Care Setting Jane Jeffrie Seley, DNP, MPH, GNP, BC-ADM, CDE, CDTC, FAAN, FAADE Diabetes Nurse Practitioner, Inpatient Diabetes
More information9/16/2013. No Conflict of Interest to Disclose
Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points
More informationStandards of Care in Diabetes What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE
Standards of Care in Diabetes 2016-- What's New? Veronica Brady, FNP-BC, PhD, BC-ADM,CDE Karmella Thomas, RD, LD,CDE Terminology No longer using the term diabetic. Diabetes does not define people. People
More informationFinding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationBreaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes
Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes Taking It to the Next Level: Pearls for Your Clinical Practice Thursday, April 23, 2009 6:00 AM - 8:00
More informationClinical Value and Evidence of Continuous Glucose Monitoring
Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationTeam-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals
Team-Based Approaches to Help Older Adults With Type 2 Diabetes Achieve Individualized Glycemic Goals 1. Which one of the agents listed here is widely considered the first-line therapy in type 2 diabetes
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationLocal Anesthesia for Dental Hygienists Session III. Altered Consciousness and Diabetes Michael E. O Brien, DDS and Frank S.
Altered Consciousness in General Dr. Michael E. O Brien Dr. Frank S. Drongowski Definitions Confusion - a mental state marked by disturbances in comprehension, understanding, and resulting in bewilderment
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationDiabetes Management in New Brunswick Nursing Homes
Diabetes Management in New Brunswick Nursing Homes Prepared by Dr. Angela McGibbon March, 2016 As the population ages and with the rising incidence of diabetes, there are increasing numbers of people with
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationA Guidance Statement from the American College of Physicians
Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy in Non-Pregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement from the American College of Physicians Timothy J. Wilt,
More informationERBP Guideline on management of diabetics with advanced CKD
ERBP Guideline on management of diabetics with advanced CKD ERBP Mission improve the outcome of patients with kidney disease in a sustainable way, through enhancing the accessibility of knowledge on patient
More information123 Are You Providing Evidence-Based Diabetes Care? - Martin
Donna Martin, DNP, RN, CDE, CMSRN Lewis University Learner will be able to: Identify current inpatient standards of care for patients with diabetes Describe causes of hyperglycemia / hypoglycemia in the
More informationSelf-Monitoring Blood Glucose (SMBG) Frequency & Pattern Tool
Self-Monitoring Blood Glucose () Pattern Recommendation: Basal Insulin Only (To Target) NPH or long-acting analogue, typically given at. at least as often as is being given. Optional, less frequent can
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationManage Diabetes with Small Changes
In This Issue: } Manage with Small Changes } The Role of Your Educator } Prediabetes: A Call to Action } Insulin and : Your Questions Answered Manage with Small Changes One man learns simple ways to keep
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationCongestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, :30 a.m. 10:15 a.m.
Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, 2017 9:30 a.m. 10:15 a.m. The prevalence of the combination of diabetes and both systolic and
More information1. Continuous Glucose Monitoring
1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationDiabetes Education Columbus Community Hospital Stacy Biesel RN, CDE
Diabetes Education Columbus Community Hospital Stacy Biesel RN, CDE Stacy Biesel, RN CDE Registered Nurse Certified Diabetes Educator Locations: Columbus Community Hospital Prairie Ridge Health Clinic
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationVICTOSA and Renal impairment DR.R.S.SAJAD
VICTOSA and Renal impairment DR.R.S.SAJAD February 2019 Main effect of GLP-1 is : Stimulating glucose dependent insulin release from the pancreatic islets. Slow gastric emptying Inhibit inappropriate
More informationOLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION
OLD AND NEW DRUGS FOR CONTROLING DIABETES THERAPEUTIC CLASSES AND MECHANISM OF ACTION Biljana Parapid, MD, PhD, FESC Belgrade University School of Medicine, Belgrade (Serbia) @biljana_parapid COI International
More informationDIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL
DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL Facility: Date: Data Collector s name: Email/Phone: Purpose: To evaluate your facility practices regarding communication of requisite diabetes
More informationHypoglycemia. Patient Education Diabetes Care Center. How to cope with low blood sugar. General Facts on Low Blood Sugar. Causes
Patient Education How to cope with low blood sugar Recognizing the causes and symptoms of hypoglycemia can help you prepare for and respond to this condition when it arises. General Facts on Low Blood
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationIn general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides.
1 2 3 In general: Hypoglycemia is common in insulin treated diabetes, but may also occur in people on oral medications, especially sulfonylureas/glinides. 4 Answer: b and c Many alcohol containing drinks
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationMOVING ON... WITH DIABETES
MOVING ON... WITH DIABETES ADOLESCENT KNOWLEDGE & SKILLS CHECKLIST (AGE 17-18 YRS) DIABETES EDUCATOR/TEAM USER GUIDE PURPOSE Provides adolescent self-assessment of learning needs prior to transition. Provides
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationDiabetes Care Center Box 356176 1959 N.E. Pacific St. Seattle, WA 98195 206-598-4882 120457 University of Washington Medical Center Diabetes Care Center Arabic r02/2000 Patient Education Diabetes Care
More informationUpdates in Diabetes Technology
Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin
More informationMultifactorial risk assessments and evidence-based interventions to address falls in primary care. Objectives. Importance
Multifactorial risk assessments and evidence-based interventions to address falls in primary care Sarah Ross, DO, MS Assistant Professor Internal Medicine, Geriatrics Nicoleta Bugnariu, PT, PhD Associate
More informationJennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii
Individualized Diabetes Treatment for the Elderly Jennifer Loh, MD, FACE Chief of Endocrinology KP Hawaii AAMD of Medical Education, KP Hawaii Extremely Relevant Baby Boomers are aging! ¼ of people age
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More information